MedPath

Elicio Therapeutics Reports Q3 EPS Significantly Above Consensus

• Elicio Therapeutics reported a Q3 EPS of -$1.39, significantly exceeding the consensus estimate of -$0.73, indicating stronger-than-expected financial performance. • The company's financial results suggest potential advancements or cost efficiencies in their pharmaceutical R&D activities. • Investors and analysts will likely scrutinize the underlying factors contributing to this earnings surprise, including clinical trial progress and operational expenses.

Elicio Therapeutics has announced its Q3 earnings per share (EPS) of -$1.39, surpassing the consensus estimate of -$0.73. The details behind this significant difference were not disclosed in the provided source. Further information on the factors contributing to this earnings surprise, such as clinical trial advancements, changes in operational expenses, or specific revenue streams, would provide a clearer understanding of Elicio's current financial standing and future prospects.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Elicio Therapeutics Completes Enrollment in Phase 2 Trial of ELI-002 for mKRAS-Driven Pancreatic Cancer

Elicio Therapeutics has completed enrollment in its Phase 2 AMPLIFY-7P study, evaluating ELI-002 7P in patients with mutant KRAS-driven pancreatic cancer at high risk of relapse.
The AMPLIFY-7P study enrolled 135 patients, randomizing them to receive ELI-002 7P or standard of care observation following surgery and chemotherapy.

Elutia Inc. Prepares for Full Launch of EluPro Antibiotic-Eluting Envelope After Positive Q3 Results

Elutia Inc. reported the first commercial use of EluPro, an FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators, with full launch slated for 2025.
Q3 financial results showed a slight decrease in overall net sales to $5.9 million, offset by a 19% increase in SimpliDerm sales and a net income improvement of $1.3 million.

Elicio Therapeutics Advances mKRAS-Targeting Cancer Vaccine, Anticipates Phase 2 Results in H1 2025

Elicio Therapeutics anticipates completing enrollment for the AMPLIFY-7P Phase 2 trial of ELI-002 in Q4 2024, with interim disease-free survival (DFS) analysis expected in H1 2025.
Data presented at SITC 2024 highlighted durable T cell responses and antigen spreading in KRAS mutant tumors following ELI-002 Phase 1a trial.

Elicio Therapeutics' ELI-002 Shows Promise in KRAS-Mutated Solid Tumors

Elicio Therapeutics' ELI-002 demonstrates durable T cell responses and potential DFS benefit in mKRAS-driven solid tumors, as presented at the SITC Annual Meeting.
The AMPLIFY-7P Phase 2 trial of ELI-002 in pancreatic ductal adenocarcinoma is enrolling faster than expected, with interim analysis anticipated in H1 2025.

iTeos Therapeutics Announces Pipeline Updates and Financial Results for Q3 2024

iTeos received EMA clearance for belrestotug 400mg + dostarlimab in the GALAXIES Lung-301 trial, enabling EU site activation.
Interim data from the inupadenant Phase 2 A2A-005 trial in 2L NSCLC were presented at ESMO-IO.

Xilio Therapeutics' Vilastobart Shows Promise in Immunotherapy-Resistant Tumors

Xilio Therapeutics announced encouraging initial Phase 1C data for vilastobart combined with atezolizumab in advanced solid tumors.
The combination demonstrated anti-tumor activity, including unconfirmed partial responses in patients with 'cold' tumors like MSS CRC.

Egetis Therapeutics' Tiratricol Shows Survival Benefit in MCT8 Deficiency

New data indicates that tiratricol (Emcitate®) treatment is associated with a threefold reduction in mortality risk for patients with MCT8 deficiency.
The European Thyroid Association has recommended tiratricol as a long-term therapy for all patients diagnosed with MCT8 deficiency in newly released guidelines.

Elicio Therapeutics to Present mKRAS Vaccine Data at Multiple Conferences

Elicio Therapeutics will present Phase I AMPLIFY-7P trial updates at the AACR Special Conference on Pancreatic Cancer, highlighting clinical actionability.
The company will also present at the RAS-Targeted Drug Development Summit, focusing on the clinical translation of its RAS-targeted Amphiphile vaccines.

Revolution Medicines' RAS(ON) Inhibitors Show Promise in Lung and Pancreatic Cancers

RMC-6236 demonstrates encouraging anti-tumor activity across multiple RAS variants (G12D, G12V, and G12R), with a 38% objective response rate in non-small cell lung cancer.
RMC-6291 shows a 50% objective response rate in lung cancer patients who progressed on prior KRAS G12C inhibitors, suggesting clinically meaningful differentiation.

Immutep's INSIGHT-003 Trial Reaches Enrollment Target in First-Line NSCLC

The INSIGHT-003 trial, evaluating eftilagimod alpha in combination with anti-PD-1 therapy and chemotherapy, has reached its enrollment target of 20 patients with 1L NSCLC.
Initial results from the triple combination therapy showed a 72.7% objective response rate and a 90.9% disease control rate in 1L NSCLC patients.

Reference News

[1]
Elicio Therapeutics reports Q3 EPS ($1.39), consensus (73c) - TipRanks.com
tipranks.com · Nov 13, 2024

Elicio's CEO, Robert Connelly, highlights significant progress in cancer immunotherapies, presenting Phase 1a trial data...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy